Form 4 for TVTX Travere Therapeutics, Inc.
Accepted 2026-09-17 21:32:52 ET · period of report 2026-09-15 · accession 0001283303-26-000010 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-09-17 21:32 | 2026-09-15 | TVTX | REED ELIZABETH E | CLO, GC | M - OptEx | $15.46 | +37.5K | 142.9K | +36% | +$579.8K |
| DMT | 2026-09-17 21:32 | 2026-09-15 | TVTX | REED ELIZABETH E | CLO, GC | S - Sale+OE | $62.34 | -37.5K | 105.4K | -26% | -$2.34M |
| DT | 2026-09-17 21:32 | 2026-09-15 | TVTX | REED ELIZABETH E | CLO, GC | M - OptEx | $0.00 | -37.5K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-15 | M | A | 37,500 | $15.46 | 142,889 | D | — | — | (F1) Includes 178 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on May 29, 2026. |
| 2 | Common | Common Stock | 2026-09-15 | S | D | 21,926 | $62.03 | 120,963 | D | — | — | (F2) This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. (F3) The weighted average sale price for the transaction reported was $62.0255, and the range of prices were between $61.44 and $62.42. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 3 | Common | Common Stock | 2026-09-15 | S | D | 13,874 | $62.63 | 107,089 | D | — | — | (F2) This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. (F4) The weighted average sale price for the transaction reported was $62.6326, and the range of prices were between $62.44 and $63.31. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 4 | Common | Common Stock | 2026-09-15 | S | D | 1,400 | $63.69 | 105,689 | D | — | — | (F2) This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. (F5) The weighted average sale price for the transaction reported was $63.6902, and the range of prices were between $63.59 and $63.85. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 5 | Common | Common Stock | 2026-09-15 | S | D | 300 | $65.31 | 105,389 | D | — | — | (F2) This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. |
| 6 | Derivative | Employee stock option (right to buy) | 2026-09-15 | M | D | 37,500 | $0.00 | 0 | D | $15.46 · — to 2030-01-31 | 37,500 Common Stock | (F6) The stock option is fully vested and exercisable. |